The Nation - News from May 24, 1989

A new combination therapy for prostate cancer approved by the government earlier this year may be especially effective in milder cases of the disease, a University of Maryland cancer researcher said. The study may represent “a significant improvement in prostate cancer treatment, especially for men with less widespread disease,” the researcher, Dr. Mario Eisenberger, said in a statement. He presented his findings to a meeting of cancer researchers in San Francisco. The combination therapy consists of a newly approved hormone-blocking drug called flutamide given along with leuprolide, the conventional treatment.